STOCK TITAN

aTyr Pharma to Present at September Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

SAN DIEGO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company will present at two investor conferences in September.

Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a company update at the H.C. Wainwright 22nd Annual Global Investment Conference, which is being held September 14-16, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, which is being held September 21-23. Both conferences will take place in a virtual format.

Details of the events are as follows:

Conference: H.C. Wainwright 22nd Annual Global Investment Conference
Date: Tuesday September 15, 2020
Presentation Time: 10:30 a.m. Eastern Time

Conference: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: Tuesday September 22, 2020
Presentation Time: 10:50 a.m. Eastern Time

A replay of the live webcast of each presentation will be available on the Investor’s section of the Company’s website at www.atyrpharma.com, and will be available for 90 days following each event.

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.

Contact: 
Ashlee Dunston 
Investor Relations, aTyr Pharma             
adunston@atyrpharma.com 


aTyr Pharma, Inc.

NASDAQ:LIFE

LIFE Rankings

LIFE Latest News

LIFE Stock Data

138.02M
60.12M
2.62%
61.73%
0.64%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO

About LIFE

atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological modulators. the company's lead candidate, resolaris™, is a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. resolaris is currently in a phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (fshd); a phase 1b/2 trial in adult patients with limb girdle muscular dystrophy (lgmd) 2b or fshd; and a phase 1b/2 trial in patients with an early onset form of fshd. to protect this pipeline, atyr built an intellectual property estate comprising 70 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by atyr. atyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation